Table 3.
Composite Cardiac Endpoint | CHF | |||||
---|---|---|---|---|---|---|
Variable | OR | 95% CI | P value | OR | 95% CI | P value |
|
|
|
||||
Age, years | 1·04 | 0·97-1·11 | 0·30 | 1·06 | 0·97-1·14 | 0·17 |
Gender | 0·43 | 0·10-1·87 | 0·26 | 0·44 | 0·08-2·35 | 0·34 |
Anthracycline | 1·38 | 0·25-7·66 | 0·72 | 0·79 | 0·09-7·28 | 0·83 |
CAD | 39·6 | 3·46-453·8 | 0·003* | 16·75 | 1·85-151·8 | 0·03* |
HTN | 4·90 | 1·06-22·71 | 0·038* | 2·63 | 0·49-14·19 | 0·27 |
β-blocker | 5·14 | 0·99-26·3 | 0·06 | 1·33 | 0·14-12·76 | 0·81 |
ACEI | 0·01 | 0·00-ND | 0·23 | 0·00 | 0·00-ND | 0·31 |
Composite cardiac endpoint = cardiovascular death, MI, and CHF.
ND = upper limit of 95% CI is not determinable because none of the six patients taking ACEI at baseline had a cardiac event.
Statistically significant univariate predictor.